Diagnostic Cancer Tests & Modalities

Overview

Accurate cancer diagnosis, tumor staging, and molecular profiling rely on a combination of radiological imaging, hematological assays, endoscopic procedures, and definitive histopathological biopsy analysis.

1. Diagnostic Imaging Modalities

Radiological imaging evaluates primary tumor dimensions, anatomical invasiveness, and distant metastases:

• Computed Tomography (CT Scan): Utilizes multi-detector X-ray arrays to generate high-resolution axial cross-sections of the chest, abdomen, and pelvis.
• Magnetic Resonance Imaging (MRI): Utilizes strong magnetic fields and radiofrequency pulses to differentiate soft tissue architecture, central nervous system tumors, musculoskeletal sarcomas, and pelvic organs.
• Positron Emission Tomography (PET/CT): Administers radiolabeled fluorodeoxyglucose (18F-FDG) to detect hypermetabolic neoplastic lesions across the whole body.
• Diagnostic Ultrasound: Employs high-frequency acoustic waves to differentiate cystic versus solid lesions in thyroid, breast, and liver tissues.
• Digital Screening & Diagnostic Mammography: Low-dose X-ray examination identifying microcalcifications and architectural tissue distortions.

2. Laboratory Biomarkers & Hematology

3. Histopathology & Tissue Biopsies

Histopathological evaluation of tissue samples by a pathologist provides the gold-standard definitive diagnosis for malignancy:

• Core Needle Biopsy (CNB): Utilizes a hollow-bore needle to extract intact tissue cores for architectural histology and immunohistochemical (IHC) staining.
• Fine Needle Aspiration (FNA): Extracts cellular aspirates for rapid cytological evaluation (e.g., thyroid nodules, superficial lymphadenopathy).
• Surgical Excisional / Incisional Biopsy: Operative removal of part or all of a suspicious mass.
• Endoscopic Biopsy: Direct visualization and mucosal sampling via colonoscopy, upper endoscopy (EGD), or bronchoscopy.

4. Advanced Multi-Cancer Early Detection (MCED)

Emerging blood-based assays analyze cell-free DNA methylation patterns, fragmentation profiles, and circulating multi-omics biomarkers to screen for signals from dozens of distinct cancer types before localized symptoms emerge.